Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
J Med Chem. 2020 Dec 10;63(23):14184-14196. doi: 10.1021/acs.jmedchem.0c00848. Epub 2020 Oct 7.
The evolution of rapidly proliferating infectious and tumorigenic diseases has resulted in an urgent need to develop new and improved intervention strategies. Among the many therapeutic strategies at our disposal, our immune system remains the gold-standard in disease prevention, diagnosis, and treatment. Vaccines have played an important role in eradicating or mitigating the spread of infectious diseases by bolstering our immunity. Despite their utility, the design and development of new, more effective vaccines remains a public health necessity. Peptide-based vaccines have been developed for a wide range of established and emerging infectious and tumorigenic diseases. New innovations in epitope design and selection, synthesis, and formulation as well as screening techniques against immunological targets have led to more effective peptide vaccines. Current and future work is geared toward the translation of peptide vaccines from preclinical to clinical utility.
快速增殖的传染性和肿瘤性疾病的演变，导致我们迫切需要开发新的和改进的干预策略。在我们可利用的众多治疗策略中，我们的免疫系统仍然是疾病预防、诊断和治疗的金标准。疫苗在通过增强我们的免疫力来消除或减轻传染病的传播方面发挥了重要作用。尽管它们很有用，但设计和开发新的、更有效的疫苗仍然是公共卫生的需要。已经为各种已建立和新兴的传染性和肿瘤性疾病开发了基于肽的疫苗。在免疫靶点的表位设计和选择、合成和配方以及筛选技术方面的新创新，导致了更有效的肽疫苗。目前和未来的工作都致力于将肽疫苗从临床前转化为临床应用。
